Vyant Bio

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded in 1999 and is headquartered in Cherry Hill, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

Cherry Hill, NJ, March 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics. Today Vyant Bio released a Letter to Shareholders from Chief Executive Officer, Jay Roberts. The complete letter follows.

Vyant Bio Issues Letter to Shareholders

Cherry Hill, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that it will be participating in The Benchmark Company Discovery One-on-One Investor Conference. The event is being held virtually on Thursday, December 2, 2021.

Vyant Bio to Present at The Benchmark Company Discovery One-on-One Investor Conference

Vyant Bio's (VYNT) CEO Jay Roberts on Q3 2021 Results - Earnings Call Transcript

Vyant Bio (NASDAQ:VYNT) Inc announced its third-quarter 2021 strategic and business updates, reporting total revenue of $1.5 million for the three months ending September 30, 2021, compared to $1.9 million in 3Q 2021.  During the quarter, the New Jersey-based company announced that it appointed Robert Fremeau as the new chief scientific officer, who will be lead Vyant Bio (NASDAQ:VYNT)'s research and development programs.

Vyant Bio reports total revenue of $1.5M in 3Q 2021, shares strategic updates

Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates

Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that it will be presenting at the Q4 Investor Summit Micro & Small Cap Conference (“Q4 Investor Summit”). The event is being held virtually from November 16-17, 2021.

Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference

CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio , Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Thursday, November 11, 2021.

Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021

Vyant Bio Inc has announced the appointment of Robert Fremeau as the company's new chief scientific officer. Vyant said Fremeau is an experienced research and development leader with over two decades of drug discovery experience in academia and industry, advancing next-generation drug development for severe neurological disorders.

Vyant Bio appoints Robert Fremeau as chief scientific officer

Vyant Bio Inc. has announced a new partnership with MASORI Therapeutics, a company focused on the pharmaceutical industry and applying artificial intelligence to achieve competitive advantage through the creation of innovative market solutions.

Vyant Bio forges partnership with MASORI Therapeutics to pursue co-development partnerships with pharma companies

Vyant Bio and Cyclica in a strategic collaboration to identify compounds to treat CDKL5 Deficiency Disorder

Vyant Bio looking to discover new therapeutics for neurological diseases and hard-to-treat cancers

HC Wainwright & Co. has initiated coverage on Vyant Bio (NASDAQ:VYNT) Inc.

HC Wainwright initiates coverage on Vyant Bio with 'Buy' recommendation and $5 price target

Vyant Bio Inc, a biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica Inc, announced a non-exclusive strategic collaboration combining Vyant Bio's patient-derived complex organoid biology alongside Cyclica's proteome-wide, Artificial Intelligence (AI) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (CDD), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure. Cherry Hill, New Jersey-based Vyant's human-first approach to novel drug discovery incorporates patient biology into the earliest steps of the process with highly functional, disease-based neural organoids; while Cyclica's proprietary machine learning platforms marry knowledge and structure-based approaches to find novel targets, uncover new uses for existing drugs, and design new molecules with high potential.

CHERRY HILL, NJ and TORONTO, CANADA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc., (Nasdaq: VYNT), a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica, Inc., the partner of choice for data driven drug discovery, today announced a non-exclusive strategic collaboration combining Vyant Bio's patient-derived complex organoid biology alongside Cyclica's proteome-wide, Artificial Intelligence (“AI”) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (“CDD”), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.

Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder

Vyant Bio Inc, an emerging global drug discovery company, posted second-quarter results that demonstrated it is in a strong financial position with $26.5 million to build a “robust pipeline” of novel therapeutics targeting neurological disorders and cancers.  For the period ended June 30, 2021, the Cherry Hill, New Jersey-based company had cash and cash equivalents totaling $26.5 million.

Vyant Bio ends 2Q with $26.5M to build a robust pipeline of novel therapeutics targeting neurological disorders and cancers

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2021 Results - Earnings Call Transcript

Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates

CHERRY HILL, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. With leading-edge capabilities in data science, biological and chemical sciences, engineering, and regulatory affairs, Vyant Bio capitalizes on in silico, human cell-derived in vitro disease models, and in vivo discovery technologies to identify novel biological targets and valuable therapeutics for patients. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Monday, August 16, 2021.

Vyant Bio Announces Investor Conference Call and Webcast for Second Quarter 2021

CHERRY HILL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery technologies, announced today that its wholly-owned subsidiary, StemoniX, Inc. (“StemoniX”), was issued US Patent No. 11054408, titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States Patent and Trademark Office (USPTO).

Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids

The stock price of Vyant Bio Inc (NASDAQ: VYNT) increased by over 8% pre-market. This is why it happened.

Vyant Bio (VYNT) Stock: Over 8% Increase Pre-Market Explanation

Cherry Hill, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other biotechnology companies to identify novel and repurposed therapeutics through the integration of human-derived biology with data science technologies and IND-enabling expertise.

Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update

CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company.

Vyant Bio to Present at BioNJ's 11th Annual BioPartnering Conference

Prometheus Biosciences

ThermoGenesis Holdings, Inc

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

3 Short Squeeze Candidates In The Health Care Sector

New collaboration mitigates risk in drug d iscovery process with artificial intelligence and in vitro “avatar” clinical trials

Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics

CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. Its newly formed Board of Directors comes from the disciplines of drug discovery and development, pharmaceuticals, and life science strategy and finance. The new board members bring decades of experience and leadership to help guide the Company in its focus on innovative and market leading drug discovery.

Vyant Bio Announces Newly Appointed Board of Directors

CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. Today, Vyant Bio announced that an investor webcast will be hosted on Tuesday, April 6, 2021.

News for Vyant Bio Stock (VYNT)